@wkissel $AFMD spinout #Amphivena was build by Affimed in a deal arrangement with $JNJ to IND-enable AMV564 but they didn't take the final option and so Affimed and investors continued own clinical development as paid consulting (my calc: ~$30m + stake for Affimed) https://t.co/1dOmAFfE6S